NIOX Group Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NIOX.L research report →
Companyinvestors.niox.com
NIOX Group Plc engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo) worldwide. Its products include NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of FeNo level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022.
- CEO
- Jonathan Charles Emms
- IPO
- 2014
- Employees
- 91
- HQ
- Oxford, GB
Price Chart
Valuation
- Market Cap
- $254.10M
- P/E
- 36.51
- P/S
- 5.22
- P/B
- 3.47
- EV/EBITDA
- 18.09
- Div Yield
- 2.57%
Profitability
- Gross Margin
- 60.78%
- Op Margin
- 21.97%
- Net Margin
- 14.37%
- ROE
- 10.14%
- ROIC
- 9.75%
Growth & Income
- Revenue
- $48.70M · 16.51%
- Net Income
- $7.00M · 89.19%
- EPS
- $0.02 · 92.05%
- Op Income
- $10.70M
- FCF YoY
- -3.70%
Performance & Tape
- 52W High
- $77.60
- 52W Low
- $53.84
- 50D MA
- $60.51
- 200D MA
- $66.97
- Beta
- -0.04
- Avg Volume
- 839.12K
Get TickerSpark's AI analysis on NIOX.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NIOX.L Coverage
We haven't published any research on NIOX.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NIOX.L Report →